A Trial of Meal Replacement at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population

NCT01729117 | Completed

• 1 other identifier: HS-08-00646
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Background and Rationale Research studies have shown that patients with type 2 diabetes (T2DM) who lose weight have better glucose control and less risk for heart disease. It has been difficult to achieve these results in a non-research setting. Meal replacements (MR) are pre-packaged meals with appropriate calories and nutrients that enhance adherence to a weight loss program by reducing decision-making and facilitating target caloric intake. The University of Southern California (USC) arm of the NIH funded Look AHEAD study at Roybal Clinic has demonstrated acceptability and success of MRs in conjunction with a structured lifestyle modification program in achieving weight loss in underserved Hispanic T2DM patients. Objectives Our short-term objective is to determine the efficacy, safety and feasibility of a 3-month full MR program in conjunction with a 1 year standardized lifestyle modification program in a clinic setting. Our longer-term goal is to acquire data for sample size and power estimates for a larger NIH- or other funded prospective, randomized trial. Study Methodology A 1-year, prospective trial study of 30 obese subjects with T2DM treated with insulin randomized to 2 groups: standard care (SC) or Meal Replacement group (MR). The SC will receive usual care at Roybal Diabetes Management Clinic (DMC). The MR will receive MRs and a lifestyle course in addition to the usual clinical care at the Roybal DMC. Phase 1 consists of 3-months 1200 -1400cal diet using full MR. Phase 2 consists of a 3-month transition to the same caloric intake using regular meals and 1 MR/day . Phase 3 consists of a 6-month weight loss maintenance period with 1 MR/day. This will be about 1400-1600 calories/day for women and 1800 to 2000 calories/day for men. Individual and group educational, support and counseling visits will be components of all 3 phases of the study. Outcomes Efficacy of the program will be determined by weight, waist measurement and waist to hip ratio, blood pressure, HbA1c, lipids, and medication use at baseline and at 3, 6, 9 and 12 months. These are all measurements that are done routinely in these patients. Safety will be determined by monitoring of adverse events. Data Analysis We will compare the outcomes between the SC and MR at 0,3,6,9 and 12 months to determine if there is evidence that the intervention improves outcomes and is safe.

Conditions

Type 2 Diabetes; Obesity

Keywords

Type 2 diabetes; Obesity; Insulin; Hispanic; Low-income; Meal replacement

Outcome Measures

Primary Outcomes (1)

• Change in BMI

  12months

Secondary Outcomes (1)

• Severe Hypoglycemic Events

  12 months

Study Arms (2)

Meal Replacement

OTHER

Meal Replacements will be provided to participants randomized to the MR group

Other: Meal Replacement

Standard Care

OTHER

Standard Care participants will receive standard care but no meal replacements

Other: Standard Care

Interventions

Meal Replacement OTHER

5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.

Also known as: HMR70 Plus products; HMR Boston, Massachusetts

Meal Replacement

Standard Care OTHER

Standard Care only

Standard Care

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Demographic
• Age \>18 years
• Enrolled in the Roybal Diabetes Management Clinic
• Self-described as Hispanic
• Willing and able to participate in Spanish language group sessions.
• Willing and able to attend study visits for the duration of the study at the allocated times.
• Willing and able to maintain a food exercise and medication log and perform and record self-monitoring of blood glucose (SMBG) Clinical
• T2DM diagnosed by fasting blood glucose \>126mg/dL or random blood glucose \>200mg/dL
• BMI\>30 kg/m2
• If a woman of childbearing potential, using effective contraception. Biochemical HbA1c 8%-12% Medication
• On insulin therapy

You may not qualify if:

• Medical conditions
• Type 1 DM
• Illness likely to lead to unstable weight or altered glucose control.
• Proliferative diabetic retinopathy on eye examination within the last 6 months.
• Gallstones suspected on clinical history or documented on ultrasound.
• Serum creatinine \>1.5mg/dL
• Symptomatic cardiovascular disease
• Documented liver disease other than fatty liver
• Lactating, pregnant or intending to become pregnant within the following year Psycho-social conditions
• Inability or unwillingness to participate in a Spanish-language lifestyle group.
• Eating disorder such as bulimia
• Uncontrolled psychiatric disorder such as severe uncontrolled depression or bipolar disorder.
• Inability to attend scheduled appointments regularly for the duration of the study Medication use
• Use of weight loss medication within previous 3 months including exenatide.
• Use of medication (other than diabetes medication) likely to lead to unstable weight or altered glucose control

Sponsors & Collaborators

• University of Southern California: lead

Study Sites (1)

Roybal Diabetes Management Clinic

Los Angeles, California, 90022, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Obesity; Insulin Resistance

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Hyperinsulinism

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Study Officials

• Elizabeth O Beale, MD

  University of Southern California

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 13, 2012
• First Posted: November 20, 2012
• Study Start: May 1, 2009
• Primary Completion: April 1, 2012
• Study Completion: April 1, 2012
• Last Updated: November 20, 2012

Record last verified: 2012-11

Locations

US (1)